J Korean Med Assoc.  2012 Jan;55(1):49-55.

Pharmacotherapy for imported parasitic diseases with drugs reserved by the government

• Kho WG

Abstract

Parasitic diseases are widely distributed throughout the world. Recently, travel abroad and migration from abroad are increasing in Korea. Therefore, it is necessary to appropriately control imported parasitic disease. The drugs for the treatment of the parasitic diseases that can be imported from abroad are reserved by the government. To guide proper treatment of parasitic diseases, recommended chemotherapy focused on these reserved drugs has been introduced. The diseases reviewed in this article include malaria, babesiosis, toxoplasmosis, leishmaniasis, Chagas disease, African sleeping sickness, filariasis, angiostrongyliasis, and fascioliasis. Because most of the parasitic diseases produce severe illness or fatal results, rapid and accurate diagnosis is important and following fully the recommended therapy is needed. The recommended drug therapy changes from time to time due to various factors, so always recognizing and applying the latest therapy and is very important.

Keyword

Imported parasitic diseases; Drug therapy; Reserved drug

MeSH Terms

Animals
Babesiosis
Chagas Disease
Fascioliasis
Filariasis
Korea
Leishmaniasis
Malaria
Parasitic Diseases
Strongylida Infections
Toxoplasmosis
Trypanosomiasis, African
Strongylida Infections

Reference

1. Ministry of Health and Welfare. Korea Center for Disease Control and Prevention. Korean Medical Association. Ministry of Health and Welfare. Korea Center for Disease Control and Prevention. Korean Medical Association. Summary of infectious diseases designated by law. Case definitions for national notifiable infectious diseases. 2010. Seoul: Munyoungsa;2–30.

2. Ministry of Health and Welfare. Korea Center for Disease Control and Prevention. Korean Medical Association. Ministry of Health and Welfare. Korea Center for Disease Control and Prevention. Korean Medical Association. Appendix 4. List of rare medicines for treatment of imported parasitic diseases. Case definitions for national notifiable infectious diseases. 2010. Seoul: Munyoungsa;308.

3. World Health Organization. World Health Organization. Antimalarial medicines. WHO model formulary 2008. 2009. Geneva: WHO Press;186–203.

4. World Health Organization. World Health Organization. Clinical disease and epidemiology. Guidelines for the treatment of malaria. 2010. 2nd ed. Geneva: WHO Press;4–5.

5. World Health Organization. World Health Organization. Health-related millennium development goals. World health statistics 2011. 2011. Geneva: WHO Press;12–21.

6. Ministry of Health and Welfare. Korea Center for Disease Control and Prevention. Ministry of Health and Welfare. Korea Center for Disease Control and Prevention. 2010 Summary of infectious diseases surveillance. Infectious diseases surveillance yearbook 2010. 2011. Seoul: Munyoungsa;15–44.

7. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin Proc. 2011. 86:561–583.

8. Dubey JP, Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int J Parasitol. 2008. 38:1257–1278.

9. Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int. 2011. 2011:571242.

10. Maya JD, Orellana M, Ferreira J, Kemmerling U, Lopez-Munoz R, Morello A. Chagas disease: Present status of pathogenic mechanisms and chemotherapy. Biol Res. 2010. 43:323–331.

11. Ramirez-Avila L, Slome S, Schuster FL, Gavali S, Schantz PM, Sejvar J, Glaser CA. Eosinophilic meningitis due to Angiostrongylus and Gnathostoma species. Clin Infect Dis. 2009. 48:322–327.

12. Kliks MM, Kroenke K, Hardman JM. Eosinophilic radiculomyeloencephalitis: an angiostrongyliasis outbreak in American Samoa related to ingestion of Achatina fulica snails. Am J Trop Med Hyg. 1982. 31:1114–1122.

13. Robinson MW, Dalton JP. Zoonotic helminth infections with particular emphasis on fasciolosis and other trematodiases. Philos Trans R Soc Lond B Biol Sci. 2009. 364:2763–2776.

14. Fairweather I. Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol. 2005. 79:227–234.